For breast cancer, a more interesting approach has been used to simultaneously target EGFR, HER2, and HER3 using a trivalent chimera made up from an EGFR siRNA positioned between two aptamers able to recognize, respectively, HER2 and HER3 (named H2EH3) [33]. This evidence concerns the gene ERBB3 and breast carcinoma.